Title: Furazabol
CAS Registry Number: 1239-29-8
CAS Name: (5a,17b)-17-Methylandrostano[2,3-c][1,2,5]oxadiazol-17-ol
Additional Names: 17b-hydroxy-17a-methyl-5a-androstano[2,3-c]furazan; androfurazanol; furazalon
Manufacturers' Codes: DH-245
Trademarks: Miotolon (Daiichi)
Molecular Formula: C20H30N2O2
Molecular Weight: 330.46
Percent Composition: C 72.69%, H 9.15%, N 8.48%, O 9.68%
Literature References: Anabolic steroid with hypocholesterolemic properties. Prepn: G. Ohta et al., BE 645743; eidem, US 3245988 (1964, 1966 both to Daiichi Seiyaku); Shimizu et al., Chem. Pharm. Bull. 13, 895 (1965); Ohta et al., ibid. 1445. Pharmacological studies: Kasahara et al., ibid. 13, 1460 (1965); 16, 1456, 1460 (1968). Toxicity: eidem, ibid. 14, 285 (1966). Metabolic studies: Takegoshi et al., ibid. 20, 1243 (1972). GC-MS determn in urine: T. Kim et al., J. Chromatogr. B 687, 79 (1996).
Properties: Needles from methanol, mp 152-153°. [a]D +39.4° (c = 1.42 in CHCl3). uv max (ethanol): 217 nm (e 4300). LD50 in mice (g/kg): 2.330 orally; >4 s.c.; 0.494 i.p. (Kasahara, 1966).
Melting point: mp 152-153°
Optical Rotation: [a]D +39.4° (c = 1.42 in CHCl3)
Absorption maximum: uv max (ethanol): 217 nm (e 4300)
Toxicity data: LD50 in mice (g/kg): 2.330 orally; >4 s.c.; 0.494 i.p. (Kasahara, 1966)
NOTE: This is a controlled substance (anabolic steroid): 21 CFR, 1308.13, as defined in 1300.01.
Furazolidone Furazolium Chloride Furcellaran Furethidine Furfural

Systematic (IUPAC) name
Clinical data
Legal status  ?
Routes Oral
Pharmacokinetic data
Half-life 4 hours
Excretion Urinary
CAS number 1239-29-8 YesY
ATC code B
PubChem CID 14708
DrugBank DB01514
ChemSpider 14032 YesY
Synonyms 17α-methyl-5α-androsta-2,3-furazan-17β-ol
Chemical data
Formula C20H30N2O2 
Mol. mass 330.4694
 YesY (what is this?)  (verify)

Furazabol (Miotolan) is a derivative of the anabolic steroid stanozolol. It differs from stanozolol by having a furazan ring system in place of the pyrazole. It has a c-17alpha methyl group, which allows it to be taken orally and causes hepatotoxicity in some individuals.[citation needed]

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of furazabol are a myth. In the 1970s, research studies showed that furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol.[citation needed] It was subsequently established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that furazabol, like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of cardiovascular disease.[citation needed]

The Canadian sprinter Ben Johnson tested positive for stanozolol after winning the gold medal in the 100 meter sprint at the 1988 Summer Olympics.[citation needed] His doctor, Dr. Jamie Astaphan, maintains that his urine sample was sabotaged because Johnson was administered furazabol, which was not an IOC banned substance at the time.[citation needed] Subsequently, training partner and fellow Charlie Francis athlete Angela Issajenko (Taylor), in her book "Running Risks" outlined a theory stating Ben Johnson actually was using stanozolol. She substantiated this by stating that her supply of what she thought was furazabol was retested following the Dubin Inquiry and was found to be stanozolol, explaining the positive test.[citation needed]